Mori K - Search Results

1

A phase II study of irinotecan and infusional cisplatin with recombinant human granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer.

Mori K, Machida S, Yoshida T, Yoshida M, Kano Y, Tominaga K. Mori K, et al. Cancer Chemother Pharmacol. 1999;43(6):467-70. doi: 10.1007/s002800050925. Cancer Chemother Pharmacol. 1999. PMID: 10321506 Clinical Trial.

2

Schedule-dependent interactions between paclitaxel and etoposide in human carcinoma cell lines in vitro.

Kano Y, Akutsu M, Suzuki K, Mori K, Yazawa Y, Tsunoda S. Kano Y, et al. Among authors: mori k. Cancer Chemother Pharmacol. 1999;44(5):381-8. doi: 10.1007/s002800050993. Cancer Chemother Pharmacol. 1999. PMID: 10501911

3

[Effective combination chemotherapy using paclitaxel in the treatment of a small-cell lung cancer patient resistant to multiple drugs].

Yoshida T, Mori K, Kamiyama Y, Tominaga K. Yoshida T, et al. Among authors: mori k. Gan To Kagaku Ryoho. 2001 Oct;28(10):1437-40. Gan To Kagaku Ryoho. 2001. PMID: 11681253 Japanese.

4

Antiemetic efficacy of alprazolam in the combination of metoclopramide plus methylprednisolone. Double-blind randomized crossover study in patients with cisplatin-induced emesis.

Mori K, Saito Y, Tominaga K. Mori K, et al. Am J Clin Oncol. 1993 Aug;16(4):338-41. doi: 10.1097/00000421-199308000-00013. Am J Clin Oncol. 1993. PMID: 8392288 Clinical Trial.

5

[Pilot phase II study of 5-day continuous infusion of cisplatin in treatment of non-small cell lung cancer].

Saito Y, Mori K, Yokoi K, Tominaga K, Miyazawa N. Saito Y, et al. Among authors: mori k. Gan To Kagaku Ryoho. 1989 May;16(5):2081-6. Gan To Kagaku Ryoho. 1989. PMID: 2543330 Japanese.

6

[Pilot study of a continuous five-day intravenous infusion of cisplatin plus vindesine in advanced non-small cell lung cancer].

Mori K, Saito Y, Yokoi K, Tominaga K, Miyazawa N. Mori K, et al. Gan To Kagaku Ryoho. 1989 Jul;16(7):2465-8. Gan To Kagaku Ryoho. 1989. PMID: 2546506 Japanese. No abstract available.

7

Recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for non-small cell lung cancer.

Mori K, Saitoh Y, Tominaga K. Mori K, et al. Eur J Cancer. 1993;29A(5):677-80. doi: 10.1016/s0959-8049(05)80345-4. Eur J Cancer. 1993. PMID: 8385969

8

Phase II study of infusional cisplatin in combination with etoposide in the treatment of small cell lung cancer.

Mori K, Ohta S, Kishiro I, Yokoyama K, Suga Y, Tominaga K. Mori K, et al. Eur J Cancer. 1995 Oct;31A(11):1781-4. doi: 10.1016/0959-8049(95)00385-v. Eur J Cancer. 1995. PMID: 8541100 Clinical Trial.

9

A phase I study of irinotecan and infusional cisplatin for advanced non-small-cell lung cancer.

Mori K, Ohnishi T, Yokoyama K, Tominaga K. Mori K, et al. Cancer Chemother Pharmacol. 1997;39(4):327-32. doi: 10.1007/s002800050579. Cancer Chemother Pharmacol. 1997. PMID: 9025773 Clinical Trial.

10

A phase I study of irinotecan and infusional cisplatin with recombinant human granulocyte colony-stimulating factor support in the treatment of advanced non-small cell lung cancer.

Mori K, Hirose T, Machida S, Yokoyama K, Tominaga K. Mori K, et al. Eur J Cancer. 1997 Mar;33(3):503-5. doi: 10.1016/s0959-8049(97)89030-2. Eur J Cancer. 1997. PMID: 9155540 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

7,577 results

Search Page

Filters